投資有価証券評価損、資本剰余金（IFRS）、外部収益 - 医薬
- 【期間】
| 年度 | 投資有価証券評価損 | 資本剰余金（IFRS） | 外部収益 - 医薬 |
|---|
| 2008/12 | - | | - | | - | |
| 2009/12 | - | | - | | - | |
| 2010/12 | - | | - | | - | |
| 2011/03 | - | | - | | - | |
| 2011/06 | -66億 | | - | | - | |
| 2011/09 | 223億 | 黒転 | - | | - | |
| 2011/12 | - | | - | | - | |
| 2012/03 | - | | - | | - | |
| 2012/06 | - | | - | | - | |
| 2012/09 | - | | - | | - | |
| 2012/12 | - | | - | | - | |
| 2013/03 | - | | - | | - | |
| 2013/06 | - | | - | | - | |
| 2013/09 | - | | - | | - | |
| 2013/12 | - | | - | | - | |
| 2014/03 | - | | - | | - | |
| 2014/06 | - | | - | | - | |
| 2014/09 | - | | - | | - | |
| 2014/12 | - | | - | | - | |
| 2015/12 | - | | - | | - | |
| 2016/06 | - | | - | | - | |
| 2016/09 | - | | - | | - | |
| 2016/12 | - | | - | | - | |
| 2017/03 | - | | - | | - | |
| 2017/06 | - | | - | | - | |
| 2017/09 | - | | - | | - | |
| 2017/12 | - | | - | | - | |
| 2018/12 | - | | 22.4億 | | 2704億 | |
| 2019/03 | - | | - | | 756億 | -72.1% |
| 2019/06 | - | | - | | 1509億 | +99.7% |
| 2019/09 | - | | - | | 2247億 | +48.9% |
| 2019/12 | - | | 249億 | 大幅増 | 3049億 | +35.7% |
| 2020/03 | - | | 249億 | +0% | 772億 | -74.7% |
| 2020/06 | - | | 249億 | +0% | 1575億 | +104.2% |
| 2020/09 | - | | 249億 | +0.2% | 2336億 | +48.3% |
| 2020/12 | - | | 249億 | +0.1% | 3178億 | +36% |
| 2021/03 | - | | 250億 | +0.2% | 810億 | -74.5% |
| 2021/06 | - | | 250億 | -0% | 1647億 | +103.5% |
| 2021/09 | - | | 251億 | +0.3% | 2536億 | +53.9% |
| 2021/12 | - | | 251億 | +0.1% | 3517億 | +38.7% |
| 2022/03 | - | | 252億 | +0.4% | 876億 | -75.1% |
| 2022/06 | - | | 253億 | +0.3% | 1850億 | +111.2% |
| 2022/09 | - | | 254億 | +0.4% | 2834億 | +53.2% |
| 2022/12 | - | | 255億 | +0.6% | 3979億 | +40.4% |
| 2023/03 | - | | 209億 | -18.1% | 934億 | -76.5% |
| 2023/06 | - | | 209億 | +0.1% | 1990億 | +113% |
| 2023/09 | - | | 210億 | +0.6% | 3058億 | +53.7% |
| 2023/12 | - | | 212億 | +0.5% | 4419億 | +44.5% |
| 2024/03 | - | | 191億 | -9.9% | 1055億 | -76.1% |
| 2024/06 | - | | 133億 | -30.4% | 2328億 | +120.7% |
